Drug Trial Radar · NCT04588922
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
May 10, 2021
Primary completion
Dec 30, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Sellas Life Sciences GroupIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five cohorts of the expansion Group 3. Groups 4 and 5 have been added to evaluate efficacy, safety, and tolerability of GFH009 in combination with venetoclax and azacitidine in newly diagnosed AML patients who are less likely to benefit from standard induction treatment with venetoclax plus HMA only regimens.
Conditions
- Hematologic Malignancies
Interventions
SLS009Drug
Solution for injection
venetoclaxDrug
Tablets
azacitidineDrug
Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability: Dose Limiting Toxicities (DLTs)Time frame: 21 to 28 days
- Safety and Tolerability: adverse events (AEs)Time frame: approximately 2 years
- Efficacy: ORRTime frame: 2 years
Locations
32 sites in 2 countries. Site status is shown where the registry gives one.
O'Neal Comprehensive Cancer Center, University of Alabama
Birmingham, Alabama · Recruiting
City of Hope - Phoenix
Goodyear, Arizona · Recruiting
Mayo Clinic
Phoenix, Arizona · Not yet recruiting
Honor Health
Scottsdale, Arizona · Recruiting
City of Hope National Medical Center
Duarte, California · Recruiting
Mayo Clinic
Jacksonville, Florida · Not yet recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
City of Hope - Atlanta
Newnan, Georgia · Recruiting
City of Hope - Chicago
Zion, Illinois · Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Terminated
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Not yet recruiting
Atlantic Health
Morristown, New Jersey · Not yet recruiting
Clinical Research Alliance, Inc.
Lake Success, New York · Terminated
New York - Presbyterian Hospital
New York, New York · Terminated
UNC School of Medicine, Division of Hematology
Chapel Hill, North Carolina · Recruiting
Bon Secours St. Francis Cancer Center
Greenville, South Carolina · Recruiting
Baylor Scott & White Health
Dallas, Texas · Recruiting
MD Anderson
Houston, Texas · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Completed
Anhui Provincial Hospital
Hefei, Anhui, China · Completed
Affiliated Cancer Hospital of Chongqing University
Chongqing, Chongqing Municipality, China · Withdrawn
Cancer prevention and treatment center of Sun Yat sen University
Guangzhou, Guangdong, China · Completed
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Completed
Affiliated Hospital of Hebei University
Baoding, Hebei, China · Completed
Henan Cancer Hospital
Zhengzhou, Henan, China · Completed
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Completed
The First Affiliated Hospital Of Nanchang University
Nanchang, Jiangxi, China · Completed
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China · Completed
Linyi Cancer Hospital
Linyi, Shandong, China · Completed
Blood disease hospital, Chinese Academy of Medical Science
Tianjin, Tianjin Municipality, China · Completed
The Second Affiliated hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.